~~<i id='B47FDD2050'><strike id='B47FDD2050'><tt id='B47FDD2050'><pre id='B47FDD2050'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

fashion

author：entertainment 2025-08-31 13:15:29 - browse：22

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： The biotech scorecard for Q3: 15 stock

focus

entertainment

hotspot

entertainment

hotspot

knowledge

AlexHogan/STATYou’rereadingthewebeditionofD.C.Diagnosis.Signupheretoreceivethisnewsletterinyourinbox

WSS

Hubble vs. James Webb telescope images: See the difference

Study: Spinal cord stimulation helps patients with paralysis walk again

'Screen and refer' systems are hurting patients

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

Being 'nonadherent' patient made me a more empathetic doctor

Health officials lay out plans to cope with respiratory virus season

hotspot

fashion

focus

Cancer drug shortages should be causing more outrage

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Hollywood unions extend contract negotiations for actors

Skip the lead apron during X

Drug repurposing or repositioning? The language matters

Dexcom's push to bring CGM to type 2 diabetes patients

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Crowdfunding for unproven stem cell procedures spreads misinformation

Walensky prepares to leave CDC — and Congress — behind

'Screen and refer' systems are hurting patients

entertainment

How the drug

Wegovy improves function in certain heart failure patients

PBMs are inflating the cost of generic drugs. They must be reined in

The biotech scorecard for Q3: 15 stock

Study: Spinal cord stimulation helps patients with paralysis walk again

Intellia plays down concerns on accidental germline transmission

hotspot

entertainment

hotspot

knowledge